Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Mediterranean Journal of Hematology and Infectious Diseases|June 18, 2019
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian PopulationElisabetta Abruzzese, Alberto Bosi, Massimo Breccia, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Blood|February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Hematological Oncology|August 8, 2025
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE StudyAlessandra Iurlo, Massimo Breccia, Fabio Stagno, et al.
Hematological Oncology|July 21, 2012
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemiaRoberto Latagliata, Massimo Breccia, Carmen Fava, et al.
Annals of Hematology|October 12, 2012
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemiaMario Tiribelli, Roberto Latagliata, Luigiana Luciano, et al.
Haematologica|January 16, 2009
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-upFrancesca Palandri, Fausto Castagnetti, Giuliana Alimena, et al.
Haematologica|July 18, 2012
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitorsAntonella Russo Rossi, Massimo Breccia, Elisabetta Abruzzese, et al.
Haematologica|June 21, 2011
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinibMassimo Breccia, Roberto Latagliata, Fabio Stagno, et al.
Plos One|June 26, 2015
Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR TechniquesAnna Grazia Recchia, Nadia Caruso, Sabrina Bossio, et al.
Pageof 14